Pharmaceutical Giant AbbVie Makes a Major Bet on a New Immunotherapy, and Its Dividend Growth Record Attracts Income-Focused Investors

Pharmaceutical Giant AbbVie Makes a Major Bet on a New Immunotherapy, and Its Dividend Growth Record Attracts Income-Focused Investors  NAI500

Summary aggregated from NAI500's public RSS feed. The full reporting belongs to NAI500 — please read it on their site.